Results 101 to 110 of about 9,247 (168)

Safety and efficacy of combined B-cell depleting therapy and daratumumab in patients with autoimmune encephalitis (RADIA): study protocol for a multicenter, randomized trial. [PDF]

Front Neurol
Xie W, Zhang LJ, Yue C, Wang B, Guo S, Lian X, Zhang C.   +6 more
europepmc   +1 more source

Anti-CD38 Therapy With Daratumumab in High-Risk IgA Nephropathy. [PDF]

Kidney Int Rep
Poux M, De Vriese AS, Cohen C, Duong Van Huyen JP, Daugas E, Jolivot A, Joher N, Matignon M, Hertig A, El Karoui K.   +9 more
europepmc   +1 more source

Monocyte-mediated metabolic rewiring via CD31-CD38 interactions promotes growth and drug-resistance in multiple myeloma. [PDF]

Hemasphere
Raoof R, Dal Collo G, Simon-Molas H, Tzortzi P, Kulaj K, Demirez EN, Massaro C, Poels R, Korst CLBM, O'Neill CA, Bruins WSC, Broekmans MEC, Behradkia P, Krevvata M, Zweegman S, Kater AP, Baglio SR, Mutis T, van de Donk NWCJ.   +18 more
europepmc   +1 more source

Refractory severe type B insulin resistance treated with daratumumab. [PDF]

JCEM Case Rep
Munugoti S, Gaddam M, Rasool N, Shevtsov P, Piranavan P, Kern PA.   +5 more
europepmc   +1 more source

Front-line treatment approaches in multiple myeloma: real-world data from a community-based oncology network. [PDF]

Front Oncol
Paulson RS, Gautam S, Medhekar R, Mahmud S, Mirsalehi A, Ensley L, Shelley B, Brisbin L, Lisi M, Khare V, Kaila S, Levy MY.   +11 more
europepmc   +1 more source

Daratumumab in relapse-refractory immune-mediated thrombotic thrombocytopenic purpura: additional evidence for its efficacy. [PDF]

Res Pract Thromb Haemost
Coppo P.
europepmc   +1 more source

MRD-negative conversion with daratumumab monotherapy in newly diagnosed multiple myeloma patients in ≥VGPR/MRD-positive after first-line therapy: Final analysis of the open-label, single-arm multicentric phase 2 trial DART4MM. [PDF]

Br J Haematol
Gozzetti A, Pacelli P, Caroni F, Raspadori D, Bestoso E, Antonioli E, Buda G, Ciofini S, Santoni A, Puccetti L, Bacchiarri F, Pengue L, Tocci D, Attucci I, Del Giudice ML, Ruggieri M, Lombardo A, Liberati AM, Candi V, Sammartano V, Cartocci A, Sicuranza A, Galimberti S, Vannucchi AM, Bocchia M.   +24 more
europepmc   +1 more source

Smoldering Multiple Myeloma: Early Intervention or Structured Surveillance? A Comprehensive Review of Evidence for and Against Early Therapy. [PDF]

Cancers (Basel)
Arora K, Soueid L, Williams L, Grover J, Basali D, Khouri J, Kaushal Y, Mazzoni S, Dahiya R, Faiman B, Valent J, Anwer F, Raza S.   +12 more
europepmc   +1 more source

Daratumumab in patients with immune thrombocytopenia: a single-center, open-label, phase 2 trial. [PDF]

EClinicalMedicine
Chen Y, Hua Z, Xu Y, Chen J, Wen Q, Sun T, Li H, Liu X, Fu R, Ju M, Xue F, Liu W, Dong H, Gu W, Dai X, Wang W, Chi Y, Pei X, Yang R, Zhang L.   +19 more
europepmc   +1 more source

Real-World Progression-Free Survival and Healthcare Resource Utilization Associated with Daratumumab Use in Transplant-Ineligible Multiple Myeloma Patients in Italy. [PDF]

Clinicoecon Outcomes Res
Perrone V, Barilà G, Franceschini L, Mele G, Mazzoni S, Cappuccilli M, Andretta M, Bacca M, Bartolini F, Barbieri A, Blasi A, Chinellato A, Dell'Orco S, Ferrante F, Lombardi R, Mancini D, Pagliaro R, Paciello A, Pastorello M, Procacci C, Ricciardulli D, Ubertazzo L, Valpondi P, Zucchi A, Degli Esposti L.   +24 more
europepmc   +1 more source